Prolonged exposure to subcutaneous and intravenous abatacept in patients with rheumatoid arthritis does not affect rates of infection, malignancy and autoimmune events: results from pooled clinical trial data
Journal article published in 2012 by
M. C. Genovese,
M. C. Hochberg,
R. B. Cohen,
M. E. Weinblatt,
J. Kaine,
E. Keystone,
P. Nash 
,
I. Delaet,
R. Alten
,
I. Delaet,
R. Alten
